Haemonetics (FRA:HAZ) Total Operating Expense: €476 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HAZ Haemonetics Corp FRA:HAZ
84 GF Score
Price €78.00
GF Value €73.15
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Haemonetics Total Operating Expense?

Haemonetics FRA:HAZ 84 Total Operating Expense is €476 Mil as of Jun. 2026. GuruFocus rates FRA:HAZ with a GF Score™ of 84/100 and a GF Value™ of €73.15 (Fairly Valued). The stock has 5 warning signs investors should review.

Haemonetics's Total Operating Expense for the three months ended in Jun. 2026 was €126 Mil. Haemonetics's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €476 Mil.

Haemonetics Total Operating Expense Related Terms

Haemonetics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Haemonetics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Total Operating Expense Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 394.40 429.12 474.95 506.69 472.45

Haemonetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.97 108.77 114.67 126.18 126.16
FRA:HAZ
84GF Score
Haemonetics Corp FRA:HAZ
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €476 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €476 Mil mean?
Haemonetics (FRA:HAZ) has a Total Operating Expense of €476 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Haemonetics and its competitors.
Is Haemonetics' Total Operating Expense too high?
Haemonetics' current Total Operating Expense is €476 Mil. Overall, Haemonetics has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Total Operating Expense compare to IRTC and ITGR?
Haemonetics' Total Operating Expense of €476 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Haemonetics and its competitors. Haemonetics's current Total Operating Expense is €476 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (FRA:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €73.15, compared to a current price of €78.00 — trading 6.6% above its estimated fair value. The current Total Operating Expense is €476 Mil. Haemonetics' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Haemonetics (FRA:HAZ), the current Total Operating Expense is €476 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (FRA:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued. The current stock price of €78.00 is trading 6.6% above its estimated GF Value™ of €73.15. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for FRA:HAZ:

  • Total Operating Expense: €476 Mil
  • GF Value™: €73.15 vs. price of €78.00 (6.6% above fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the FRA:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
84GF Score

Get the complete analysis for FRA:HAZ

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€73.15
GF Value